Colonization With Staphylococcus aureus in Atopic Dermatitis Patients: Attempts to Reveal the Unknown

Atopic dermatitis (AD) patients are massively colonized with ( ) in lesional and non-lesional skin. A skin infection may become systemic if left untreated. Of interest, the incidence of multi-drug resistant (MRSA) in AD patients is higher as compared to a healthy population, which makes treatment ev...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 11; p. 567090
Main Authors Ogonowska, Patrycja, Gilaberte, Yolanda, Barańska-Rybak, Wioletta, Nakonieczna, Joanna
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 11.01.2021
Subjects
antistaphylococcal photodynamic treatment
epidemiology of S. aureus
Microbiology
MRSA
staphylococcal enterotoxins
virulence factor
epidemiology of S. aureus
staphylococcal enterotoxins
virulence factor
antistaphylococcal photodynamic treatment
MRSA
Online AccessGet full text

Cover

More Information
Summary:Atopic dermatitis (AD) patients are massively colonized with ( ) in lesional and non-lesional skin. A skin infection may become systemic if left untreated. Of interest, the incidence of multi-drug resistant (MRSA) in AD patients is higher as compared to a healthy population, which makes treatment even more challenging. Information on the specific genetic background of accompanying and/or causing AD flares would be of great importance in terms of possible treatment option development. In this review, we summarized the data on the prevalence of in general in AD skin, and the prevalence of specific clones that might be associated with flares of eczema. We put our special interest in the presence and role of staphylococcal enterotoxins as important virulence factors in the epidemiology of AD-derived . Also, we summarize the present and potentially useful future anti-staphylococcal treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Fabian Cieplik, University Medical Center Regensburg, Germany
Reviewed by: Teruaki Nakatsuji, University of California, San Diego, United States; Michael Otto, National Institutes of Health (NIH), United States
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2020.567090